天坛生物：人凝血酶原复合物完成Ⅲ期临床试验

Core Viewpoint - TianTan Biological (600161) announced the completion of Phase III clinical trials for its "Prothrombin Complex Concentrate," demonstrating significant efficacy and safety for patients with Hemophilia B [1] Group 1: Clinical Trial Results - The clinical trial results indicate that the infusion significantly increases coagulation factor levels II/VII/IX/X in patients with Hemophilia B [1] - The treatment improves coagulation function and alleviates bleeding symptoms and signs in Hemophilia B patients [1] Group 2: Safety Analysis - Safety analysis results show that the drug has good safety profiles during clinical application for Hemophilia B patients [1]